Flow Traders U.S.’s Franklin Genomic Advancements ETF HELX Stock Holding History
Bought
Maintained
Sold
Other funds holding HELX
APA
BFEC
GWM
SWM
Flow Traders U.S.'s HELX Position: Q1 2022 in Review
Flow Traders U.S. sold out of Franklin Genomic Advancements ETF (HELX) in Q1 2022, closing a stake of 6,488 shares — an estimated $315K sold.
Flow Traders U.S. first reported a position in HELX in Q1 2021 and held it in 4 quarters. The position peaked at $348K in Q2 2021. 8 funds tracked by Wall St. Rank hold HELX as of Q1 2022.
- Flow Traders U.S. reported no remaining Franklin Genomic Advancements ETF position as of Q1 2022 after selling out during the quarter.
- Flow Traders U.S. sold 6,488 Franklin Genomic Advancements ETF shares in Q1 2022, an estimated $315K.
- Flow Traders U.S. first reported a position in Franklin Genomic Advancements ETF in Q1 2021 and held it in 4 quarters.
- Flow Traders U.S.'s Franklin Genomic Advancements ETF position peaked at $348K in Q2 2021.
- 8 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q1 2022.
Based on Flow Traders U.S.'s 13F filing for Q1 2022, filed 13 May 2022.